ABT
Abbott Laboratories
NYSE · Healthcare · Medical - Devices · US
$108.32
−0.43%Year over year
Reported trailing growth
- Revenue
- +8.1%
- EBITDA
- -14.4%
- EBIT
- +5.1%
- EPS
- -61.4%
- Free cash flow
- +28.7%
- Operating cash flow
- +9.6%
Forward estimates
Based on analyst estimates
- Revenue
- +13.4%
- EBITDA
- +54.1%
- EPS
- +86.3%
Three-year CAGR
- Revenue
- +0.5%
- EBITDA
- -0.9%
- EBIT
- -1.3%
- Net income
- -2.0%
- EPS
- -1.7%
- Free cash flow
- -1.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026